| Bioactivity | CBP-1018 is a PDC (peptide-drug conjugate) formed by dual ligands targeting FRα/TRPV6 conjugated with Monomethyl auristatin E (HY-15162) through a linker (HY-78738). CBP-1018 holds potential for research in the field of breast cancer[1]. |
| CAS | 2923068-30-6 |
| Formula | C132H192N30O38S |
| Molar Mass | 2839.18 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li X, et al. LC-MS/MS method for dual-ligand peptide-drug CBP-1018 and its deconjugated payload MMAE including sample stabilization strategy for its MC-Val-Cit-PABC linker. Talanta. 2024 Nov 1;279:126596. |
CBP-1018
CAS: 2923068-30-6 F: C132H192N30O38S W: 2839.18
CBP-1018 is a PDC (peptide-drug conjugate) formed by dual ligands targeting FRα/TRPV6 conjugated with Monomethyl aurist
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.